Bristol Myers SquibbBMY

NYSE · USA · Segment 2 of 8 in the Medicine, pharma & life science value chain: Big pharma

Opdivo made the company's name in oncology. Immunology and haematology fill out the portfolio, with neuroscience coming through the pipeline.

Big pharma: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.

Key metrics

Market cap

$132B

Price

$67.28

Today

+0.4%

Return YTD

+24.2%

Return 1Y

+38.4%

P/E

14.2

P/S

2.7

P/B

5.9

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Big pharmaOncologyImmunology

In the value chain

Products & services

Oncology (Opdivo)
Immunology
Hematology

Competitors

Merck
Pfizer
AstraZeneca

Risks

Patent cliff (Eliquis, Opdivo)
Pipeline transition

Supply chain

Supplies →

McKessonMCK CencoraCOR

← Suppliers

RevvityRVTY Charles River LaboratoriesCRL West Pharmaceutical ServicesWST

Full supply chain for BMY →

Same segment: Big pharma

Johnson & JohnsonJNJ AbbVieABBV Merck & Co.MRK PfizerPFE ZoetisZTS

Compare BMY

BMY vs JNJ BMY vs ABBV BMY vs MRK BMY vs PFE BMY vs ZTS

See where Bristol Myers Squibb sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →